HebeCell develops a patented ProtoNK™ manufacturing platform that produces allogeneic natural killer (NK) cells for the treatment of cancer and viral infections. This technology enables scalable production of potent NK cells, providing off-the-shelf therapeutic options for patients with incurable diseases.
Funding
$63M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JPFounders
Product
Problem
Current methods of producing natural killer (NK) cells for cancer and viral infection treatments often struggle with scalability and can result in less potent, exhausted cells due to extensive expansion processes. Existing autologous CAR-T cell therapies are patient-specific, limiting immediate availability and increasing treatment complexity.
Solution
HebeCell utilizes its patented ProtoNK™ manufacturing platform to generate allogeneic NK cells for off-the-shelf cancer and viral infection therapies. This platform mimics in vivo hematopoiesis within a single-use bioreactor, enabling scalable production of NK cells with limited expansion. By minimizing expansion, the resulting ProtoNK™ cells are more potent and less exhausted compared to traditional methods. The allogeneic nature of ProtoNK™ cells allows for immediate use in any patient, offering a readily available treatment option.
Target Audience
The primary target audience includes oncology departments in hospitals and medical professionals seeking readily available, off-the-shelf NK cell therapies for cancer and viral infections.
Features
- Patented ProtoNK™ manufacturing platform for scalable NK cell production
- Single-use bioreactor system mimicking in vivo hematopoiesis
- Limited expansion process resulting in more potent and less exhausted NK cells
- Allogeneic NK cells suitable for off-the-shelf therapeutic applications
- NK Functional Assay for quality control